{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Objective Response Rate,"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Partial response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"ORR (confirmed CR+PR) to tazemetostat in subjects with relapsed/refractory malignant mesothelioma using disease-appropriate standardized response criteria (modified RECIST or RECIST 1.1)","groups":[{"description":"Subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status","id":"OG000","title":"Part 1"},{"description":"Subjects with relapsed or refractory BAP1-deficient malignant mesothelioma","id":"OG001","title":"Part 2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Assessed every 6 weeks for duration of study participation which is estimated to be 12 months","title":"Part 1 and 2: Objective Response Rate (ORR; Complete Response + Partial Response [CR + PR])","type":"SECONDARY","unitOfMeasure":"Participants"}